Physician profile
Dan Reinstein
NPI 1770900995
$2,636,509.64
in general payments reported to CMS, 2019-2025
4 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407K · 2020: $743K · 2021: $341K · 2022: $389K · 2023: $414K · 2024: $341K · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $459K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $295K · Travel and Lodging: $1,768 · Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $458,705.31 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $294,530.95 |
| Travel and Lodging | $1,767.81 |
| Food and Beverage | $730.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $2,247,262.89 | 2019-2024 | Visumax, Mel 90, Atlas 500 |
| Carl Zeiss Meditec, INC. | $388,826.05 | 2019-2025 | Visumax |
| Carl Zeiss Meditec USA, INC. | $380.74 | 2023-2024 | Mel 90 |
| Pfizer INC. | $39.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Reinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.